2019
The life-threatening eruptions of immune checkpoint inhibitor therapy
Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics In Dermatology 2019, 38: 94-104. PMID: 32197753, DOI: 10.1016/j.clindermatol.2019.10.015.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAcute generalized exanthematous pustulosisSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeToxic epidermal necrolysisManagement of irAEsImmune checkpoint inhibitor therapyCell death ligand 1Generalized exanthematous pustulosisCheckpoint inhibitor therapyCutaneous adverse reactionsDeath ligand 1Life-threatening presentationCell death 1Cytotoxic T lymphocytesLife-threatening eruptionsDermatologic toxicitiesExanthematous pustulosisICPI therapyNeutrophilic dermatosisCheckpoint inhibitorsEpidermal necrolysisAdverse eventsCutaneous eruption
2018
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy